BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Wedbush Analyst Says

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its price objective upped by research analysts at Wedbush from $16.00 to $18.00 in a report released on Monday,Benzinga reports. The firm presently has an "outperform" rating on the biotechnology company's stock. Wedbush's target price indicates a potential upside of 92.31% from the company's previous close.

A number of other equities research analysts have also recently commented on BCRX. Royal Bank Of Canada reiterated an "outperform" rating and set a $13.00 price target (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Wall Street Zen cut BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, Barclays upped their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $16.89.

BioCryst Pharmaceuticals Trading Down 3.1%

BioCryst Pharmaceuticals stock opened at $9.36 on Monday. BioCryst Pharmaceuticals has a 12 month low of $6.02 and a 12 month high of $12.50. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -36.00, a price-to-earnings-growth ratio of 1.87 and a beta of 1.10. The business's fifty day simple moving average is $9.96 and its two-hundred day simple moving average is $8.56.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers grew its holdings in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Rhumbline Advisers now owns 309,132 shares of the biotechnology company's stock worth $2,325,000 after acquiring an additional 5,615 shares during the period. Los Angeles Capital Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 16.9% during the 4th quarter. Los Angeles Capital Management LLC now owns 101,188 shares of the biotechnology company's stock valued at $761,000 after purchasing an additional 14,655 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $192,000. Charles Schwab Investment Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock valued at $14,890,000 after purchasing an additional 91,998 shares during the last quarter. Finally, Arizona State Retirement System lifted its stake in shares of BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company's stock worth $429,000 after purchasing an additional 3,518 shares during the period. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.